Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxyphencyclimine is a synthetic anticholinergic and antimuscarinic agent used primarily for the treatment of peptic ulcer disease and gastrointestinal spasms. It acts as an antagonist at muscarinic acetylcholine receptors (M1, M2, and M3 subtypes), thereby inhibiting vagally mediated reflexes by blocking the action of acetylcholine. This results in reduced gastric acid secretion and pronounced antispasmodic effects on smooth muscle in the gastrointestinal tract. Oxyphencyclimine was marketed under the brand name Daricon but has been discontinued in some regions such as the USA[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxyphencyclimine.